ES2340902B1 - Composicion farmaceutica con glicosaminoglicanos y su uso en tratamiento de ulceras cronicas. - Google Patents
Composicion farmaceutica con glicosaminoglicanos y su uso en tratamiento de ulceras cronicas. Download PDFInfo
- Publication number
- ES2340902B1 ES2340902B1 ES200802002A ES200802002A ES2340902B1 ES 2340902 B1 ES2340902 B1 ES 2340902B1 ES 200802002 A ES200802002 A ES 200802002A ES 200802002 A ES200802002 A ES 200802002A ES 2340902 B1 ES2340902 B1 ES 2340902B1
- Authority
- ES
- Spain
- Prior art keywords
- sulfo
- proportion
- glucosamine
- heparin
- ulcers
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000011282 treatment Methods 0.000 title claims abstract description 67
- 230000001684 chronic effect Effects 0.000 title claims abstract description 31
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 16
- 208000025865 Ulcer Diseases 0.000 claims abstract description 93
- 231100000397 ulcer Toxicity 0.000 claims abstract description 78
- 229940127215 low-molecular weight heparin Drugs 0.000 claims abstract description 61
- 208000008960 Diabetic foot Diseases 0.000 claims abstract description 53
- 239000000203 mixture Substances 0.000 claims abstract description 39
- 229920002683 Glycosaminoglycan Polymers 0.000 claims abstract description 37
- 239000003814 drug Substances 0.000 claims abstract description 15
- 238000004519 manufacturing process Methods 0.000 claims abstract description 13
- 208000004210 Pressure Ulcer Diseases 0.000 claims abstract description 9
- 150000002772 monosaccharides Chemical class 0.000 claims description 68
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 58
- 229920000669 heparin Polymers 0.000 claims description 47
- 229960002897 heparin Drugs 0.000 claims description 36
- AEMOLEFTQBMNLQ-CLQWQSTFSA-N l-iduronic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@H](O)[C@@H](O)[C@@H]1O AEMOLEFTQBMNLQ-CLQWQSTFSA-N 0.000 claims description 28
- PRDZVHCOEWJPOB-QZABAPFNSA-N n-sulfo-d-glucosamine Chemical compound OC[C@H]1O[C@@H](O)[C@H](NS(O)(=O)=O)[C@@H](O)[C@@H]1O PRDZVHCOEWJPOB-QZABAPFNSA-N 0.000 claims description 27
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 claims description 26
- 239000002253 acid Substances 0.000 claims description 26
- AEMOLEFTQBMNLQ-WAXACMCWSA-N alpha-D-glucuronic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-WAXACMCWSA-N 0.000 claims description 26
- 239000003055 low molecular weight heparin Substances 0.000 claims description 26
- AJBMJMMLWNUEAC-IVMDWMLBSA-N OC[C@H]1OC(O)[C@H](NS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@@H]1O Chemical group OC[C@H]1OC(O)[C@H](NS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@@H]1O AJBMJMMLWNUEAC-IVMDWMLBSA-N 0.000 claims description 22
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 claims description 20
- 229950006780 n-acetylglucosamine Drugs 0.000 claims description 20
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 claims description 17
- 150000002016 disaccharides Chemical group 0.000 claims description 11
- 238000007920 subcutaneous administration Methods 0.000 claims description 3
- 206010011985 Decubitus ulcer Diseases 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 229940079593 drug Drugs 0.000 abstract description 12
- 206010012601 diabetes mellitus Diseases 0.000 description 77
- 241000700159 Rattus Species 0.000 description 52
- 230000035876 healing Effects 0.000 description 49
- 230000000694 effects Effects 0.000 description 43
- 229960001318 fondaparinux Drugs 0.000 description 42
- KANJSNBRCNMZMV-ABRZTLGGSA-N fondaparinux Chemical compound O[C@@H]1[C@@H](NS(O)(=O)=O)[C@@H](OC)O[C@H](COS(O)(=O)=O)[C@H]1O[C@H]1[C@H](OS(O)(=O)=O)[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O[C@@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O4)NS(O)(=O)=O)[C@H](O3)C(O)=O)O)[C@@H](COS(O)(=O)=O)O2)NS(O)(=O)=O)[C@H](C(O)=O)O1 KANJSNBRCNMZMV-ABRZTLGGSA-N 0.000 description 41
- 238000000034 method Methods 0.000 description 25
- 229960003616 bemiparin Drugs 0.000 description 19
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- 208000027418 Wounds and injury Diseases 0.000 description 17
- 230000007423 decrease Effects 0.000 description 17
- 102000004411 Antithrombin III Human genes 0.000 description 16
- 108090000935 Antithrombin III Proteins 0.000 description 16
- 229960005348 antithrombin iii Drugs 0.000 description 16
- 241000700157 Rattus norvegicus Species 0.000 description 15
- 239000000243 solution Substances 0.000 description 15
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 15
- 229960001052 streptozocin Drugs 0.000 description 15
- 238000001228 spectrum Methods 0.000 description 14
- 230000036269 ulceration Effects 0.000 description 14
- XLYOFNOQVPJJNP-ZSJDYOACSA-N Heavy water Chemical compound [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 13
- 150000002482 oligosaccharides Polymers 0.000 description 13
- 210000001519 tissue Anatomy 0.000 description 13
- 208000003790 Foot Ulcer Diseases 0.000 description 12
- 208000032843 Hemorrhage Diseases 0.000 description 12
- 238000002266 amputation Methods 0.000 description 11
- 208000034158 bleeding Diseases 0.000 description 11
- 230000000740 bleeding effect Effects 0.000 description 11
- 238000000990 heteronuclear single quantum coherence spectrum Methods 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- 230000008929 regeneration Effects 0.000 description 11
- 238000011069 regeneration method Methods 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 10
- 206010052428 Wound Diseases 0.000 description 10
- 230000002785 anti-thrombosis Effects 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 239000008103 glucose Substances 0.000 description 10
- 230000003993 interaction Effects 0.000 description 10
- 238000011321 prophylaxis Methods 0.000 description 10
- 230000004075 alteration Effects 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 230000001172 regenerating effect Effects 0.000 description 9
- 206010002091 Anaesthesia Diseases 0.000 description 8
- 108010074860 Factor Xa Proteins 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- 230000037005 anaesthesia Effects 0.000 description 8
- 230000006378 damage Effects 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 210000003491 skin Anatomy 0.000 description 8
- 150000001720 carbohydrates Chemical group 0.000 description 7
- 229960004969 dalteparin Drugs 0.000 description 7
- 230000003247 decreasing effect Effects 0.000 description 7
- 208000014674 injury Diseases 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- 238000011002 quantification Methods 0.000 description 7
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 230000036592 analgesia Effects 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 229960003299 ketamine Drugs 0.000 description 6
- 230000003902 lesion Effects 0.000 description 6
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 6
- 229960001600 xylazine Drugs 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 208000007536 Thrombosis Diseases 0.000 description 5
- 239000003146 anticoagulant agent Substances 0.000 description 5
- 230000000302 ischemic effect Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 108010081589 Becaplermin Proteins 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- 238000005481 NMR spectroscopy Methods 0.000 description 4
- 206010040943 Skin Ulcer Diseases 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 230000008034 disappearance Effects 0.000 description 4
- 239000003102 growth factor Substances 0.000 description 4
- 208000028867 ischemia Diseases 0.000 description 4
- 229920001542 oligosaccharide Polymers 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate group Chemical group S(=O)(=O)([O-])[O-] QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 4
- 238000005670 sulfation reaction Methods 0.000 description 4
- 230000000472 traumatic effect Effects 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 3
- 101001052035 Homo sapiens Fibroblast growth factor 2 Proteins 0.000 description 3
- 206010050502 Neuropathic ulcer Diseases 0.000 description 3
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 239000012736 aqueous medium Substances 0.000 description 3
- 238000007068 beta-elimination reaction Methods 0.000 description 3
- 238000004140 cleaning Methods 0.000 description 3
- 230000002354 daily effect Effects 0.000 description 3
- 230000002500 effect on skin Effects 0.000 description 3
- 230000008030 elimination Effects 0.000 description 3
- 238000003379 elimination reaction Methods 0.000 description 3
- 229960000610 enoxaparin Drugs 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 102000037865 fusion proteins Human genes 0.000 description 3
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 210000003141 lower extremity Anatomy 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 239000000902 placebo Substances 0.000 description 3
- 229940068196 placebo Drugs 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 238000004153 renaturation Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 229960005062 tinzaparin Drugs 0.000 description 3
- 230000017423 tissue regeneration Effects 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- 208000004043 venous thromboembolism Diseases 0.000 description 3
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- 200000000007 Arterial disease Diseases 0.000 description 2
- 206010063560 Excessive granulation tissue Diseases 0.000 description 2
- 229920001499 Heparinoid Polymers 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- -1 N-sulfo-D-Glucosamine N-acetyl-D-Glucosamine Chemical compound 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- IOVCWXUNBOPUCH-UHFFFAOYSA-N Nitrous acid Chemical compound ON=O IOVCWXUNBOPUCH-UHFFFAOYSA-N 0.000 description 2
- 102100040990 Platelet-derived growth factor subunit B Human genes 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- DQTRACMFIGDHSN-IVMDWMLBSA-N [(3r,4r,5s,6r)-2,4,5-trihydroxy-6-(sulfooxymethyl)oxan-3-yl]sulfamic acid Chemical class OC1O[C@H](COS(O)(=O)=O)[C@@H](O)[C@H](O)[C@H]1NS(O)(=O)=O DQTRACMFIGDHSN-IVMDWMLBSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 2
- 229940030225 antihemorrhagics Drugs 0.000 description 2
- 229960004787 becaplermin Drugs 0.000 description 2
- HYNPZTKLUNHGPM-KKERQHFVSA-N becaplermin Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](Cc2cnc[nH]2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N3CCC[C@H]3C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]5CCCN5C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H]6CCCN6C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CS)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CS)NC(=O)[C@H](CS)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CS)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]7CCCN7C(=O)[C@H](Cc8c[nH]c9c8cccc9)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CS)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCSC)NC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)N HYNPZTKLUNHGPM-KKERQHFVSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 231100000749 chronicity Toxicity 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 238000003381 deacetylation reaction Methods 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 210000004207 dermis Anatomy 0.000 description 2
- 230000003292 diminished effect Effects 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 210000001126 granulation tissue Anatomy 0.000 description 2
- 230000000025 haemostatic effect Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 239000002554 heparinoid Substances 0.000 description 2
- 238000005570 heteronuclear single quantum coherence Methods 0.000 description 2
- 238000011542 limb amputation Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000002981 neuropathic effect Effects 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 229960005489 paracetamol Drugs 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-O pyridinium Chemical compound C1=CC=[NH+]C=C1 JUJWROOIHBZHMG-UHFFFAOYSA-O 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000010410 reperfusion Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 230000019635 sulfation Effects 0.000 description 2
- AKEJUJNQAAGONA-UHFFFAOYSA-N sulfur trioxide Chemical compound O=S(=O)=O AKEJUJNQAAGONA-UHFFFAOYSA-N 0.000 description 2
- 229910021653 sulphate ion Inorganic materials 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 230000000287 tissue oxygenation Effects 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 208000019553 vascular disease Diseases 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- FUSNOPLQVRUIIM-UHFFFAOYSA-N 4-amino-2-(4,4-dimethyl-2-oxoimidazolidin-1-yl)-n-[3-(trifluoromethyl)phenyl]pyrimidine-5-carboxamide Chemical compound O=C1NC(C)(C)CN1C(N=C1N)=NC=C1C(=O)NC1=CC=CC(C(F)(F)F)=C1 FUSNOPLQVRUIIM-UHFFFAOYSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 208000004476 Acute Coronary Syndrome Diseases 0.000 description 1
- 108010001781 Apligraf Proteins 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 206010012655 Diabetic complications Diseases 0.000 description 1
- 206010060803 Diabetic foot infection Diseases 0.000 description 1
- 206010056340 Diabetic ulcer Diseases 0.000 description 1
- 206010014522 Embolism venous Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000385 Fibroblast growth factor 7 Proteins 0.000 description 1
- 102000003972 Fibroblast growth factor 7 Human genes 0.000 description 1
- 108010022901 Heparin Lyase Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 208000035901 Ischaemic ulcer Diseases 0.000 description 1
- AEMOLEFTQBMNLQ-HNFCZKTMSA-N L-idopyranuronic acid Chemical group OC1O[C@@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-HNFCZKTMSA-N 0.000 description 1
- OXFPUTVGMDTUNO-SKNVOMKLSA-N L-iduronic acid 2-sulfate Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](C(O)=O)OS(O)(=O)=O OXFPUTVGMDTUNO-SKNVOMKLSA-N 0.000 description 1
- 230000006179 O-acylation Effects 0.000 description 1
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 1
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- 206010040893 Skin necrosis Diseases 0.000 description 1
- 102000052126 Sodium-Hydrogen Exchangers Human genes 0.000 description 1
- 102100030980 Sodium/hydrogen exchanger 1 Human genes 0.000 description 1
- 108091006672 Sodium–hydrogen antiporter Proteins 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 208000000558 Varicose Ulcer Diseases 0.000 description 1
- VPSCBZXJXYLJOH-IVMDWMLBSA-N [(3R,4R,5R,6R)-2,5-dihydroxy-4-sulfooxy-6-(sulfooxymethyl)oxan-3-yl]sulfamic acid Chemical compound OC1O[C@H](COS(O)(=O)=O)[C@@H](O)[C@H](OS(O)(=O)=O)[C@H]1NS(O)(=O)=O VPSCBZXJXYLJOH-IVMDWMLBSA-N 0.000 description 1
- UZUBNIPDAIVWIE-IVMDWMLBSA-N [(3r,4r,5r,6r)-3-amino-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl] hydrogen sulfate Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1OS(O)(=O)=O UZUBNIPDAIVWIE-IVMDWMLBSA-N 0.000 description 1
- IIACRCGMVDHOTQ-KHWXYDKHSA-N [35S](N)(O)(=O)=O Chemical class [35S](N)(O)(=O)=O IIACRCGMVDHOTQ-KHWXYDKHSA-N 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- GETQZCLCWQTVFV-UHFFFAOYSA-N anhydrous trimethylamine Natural products CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 1
- 230000001858 anti-Xa Effects 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000002429 anti-coagulating effect Effects 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 229940127217 antithrombotic drug Drugs 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 229940110519 bemiparin sodium Drugs 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-QZABAPFNSA-N beta-D-glucosamine Chemical compound N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-QZABAPFNSA-N 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 230000008081 blood perfusion Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000001804 debridement Methods 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N glucosamine group Chemical group OC1[C@H](N)[C@@H](O)[C@H](O)[C@H](O1)CO MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 150000004676 glycans Polymers 0.000 description 1
- 230000002641 glycemic effect Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 108010093115 growth factor-activatable Na-H exchanger NHE-1 Proteins 0.000 description 1
- 239000013003 healing agent Substances 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 230000001371 heparinic effect Effects 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 description 1
- 229940099552 hyaluronan Drugs 0.000 description 1
- 239000012493 hydrazine sulfate Substances 0.000 description 1
- 229910000377 hydrazine sulfate Inorganic materials 0.000 description 1
- 238000006698 hydrazinolysis reaction Methods 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- DXASQZJWWGZNSF-UHFFFAOYSA-N n,n-dimethylmethanamine;sulfur trioxide Chemical compound CN(C)C.O=S(=O)=O DXASQZJWWGZNSF-UHFFFAOYSA-N 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000014508 negative regulation of coagulation Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 238000012148 non-surgical treatment Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000005022 packaging material Substances 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000008289 pathophysiological mechanism Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000009522 phase III clinical trial Methods 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 1
- 150000004804 polysaccharides Polymers 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 208000012802 recumbency Diseases 0.000 description 1
- 229940116157 regranex Drugs 0.000 description 1
- 230000000250 revascularization Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000007142 ring opening reaction Methods 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000009331 sowing Methods 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 230000009424 thromboembolic effect Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 238000007631 vascular surgery Methods 0.000 description 1
- 230000037314 wound repair Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/727—Heparin; Heparan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (19)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES200802002A ES2340902B1 (es) | 2008-07-01 | 2008-07-01 | Composicion farmaceutica con glicosaminoglicanos y su uso en tratamiento de ulceras cronicas. |
| US13/001,895 US20110201572A1 (en) | 2008-07-01 | 2009-06-30 | Pharmaceutical composition with glycosaminoglycans and use thereof in the treatment of chronic ulcers |
| EP09772593.1A EP2308497B1 (en) | 2008-07-01 | 2009-06-30 | Pharmaceutical composition with glycosaminoglycans and use thereof in the treatment of chronic ulcers |
| PCT/ES2009/070264 WO2010000904A1 (es) | 2008-07-01 | 2009-06-30 | Composición farmacéutica con glicosaminoglicanos y su uso en tratamiento de úlceras crónicas |
| CN2009801338633A CN102176915A (zh) | 2008-07-01 | 2009-06-30 | 具有糖胺聚糖的药物组合物及其在治疗慢性溃疡中的应用 |
| RU2011103459/15A RU2011103459A (ru) | 2008-07-01 | 2009-06-30 | Фармацевтическая композиция с гликозаминогликанами и ее применение при лечении хронических язв |
| MX2010014552A MX2010014552A (es) | 2008-07-01 | 2009-06-30 | Composicion farmaceutica con glicosaminoglicanos y su uso en tratamiento de ulceras cronicas. |
| PT97725931T PT2308497E (pt) | 2008-07-01 | 2009-06-30 | Composição farmacêutica com glicosaminoglicanos e sua utilização no tratamento das úlceras crónicas |
| PCT/ES2009/070266 WO2010000906A1 (es) | 2008-07-01 | 2009-06-30 | Composición farmacéutica con glicosaminoglicanos y su uso en el tratamiento de úlceras crónicas |
| PL09772593T PL2308497T3 (pl) | 2008-07-01 | 2009-06-30 | Kompozycja farmaceutyczna zawierająca glikozoaminoglikany oraz jej zastosowanie w leczeniu przewlekłych owrzodzeń |
| JP2011515493A JP2011526608A (ja) | 2008-07-01 | 2009-06-30 | グリコサミノグリカンを含む医薬組成物及び慢性潰瘍の処理へのその使用 |
| BRPI0913839A BRPI0913839A2 (pt) | 2008-07-01 | 2009-06-30 | composição farmacêutica com glicosaminoglicanos e uso da mesma no tratamento de úlceras crônicas |
| PCT/ES2009/070265 WO2010000905A1 (es) | 2008-07-01 | 2009-06-30 | Composición farmacéutica con glicosaminoglicanos y su uso en tratamiento de úlceras crónicas |
| AU2009265623A AU2009265623B2 (en) | 2008-07-01 | 2009-06-30 | Pharmaceutical composition with glycosaminoglycans and use thereof in the treatment of chronic ulcers |
| ES09772593.1T ES2476966T3 (es) | 2008-07-01 | 2009-06-30 | Composición farmacéutica con glicosaminoglicanos y su uso en tratamiento de úlceras crónicas |
| CA2766483A CA2766483C (en) | 2008-07-01 | 2009-06-30 | Pharmaceutical composition with glycosaminoglycans and use thereof in the treatment of chronic ulcers |
| DK09772593.1T DK2308497T3 (da) | 2008-07-01 | 2009-06-30 | Farmaceutisk sammensætning omfattende glycosaminoglycaner og brug heraf ved behandling af kroniske mavesår |
| US14/018,840 US9211305B2 (en) | 2008-07-01 | 2013-09-05 | Pharmaceutical compositions with glycosaminoglycans and use thereof in the treatment of chronic ulcers |
| CY20141100529T CY1115780T1 (el) | 2008-07-01 | 2014-07-14 | Φαρμακευτικη συνθεση με glycosαμινοglycans και χρηση αυτης για την θεραπεια χρονιων ελκων |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES200802002A ES2340902B1 (es) | 2008-07-01 | 2008-07-01 | Composicion farmaceutica con glicosaminoglicanos y su uso en tratamiento de ulceras cronicas. |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| ES2340902A1 ES2340902A1 (es) | 2010-06-10 |
| ES2340902B1 true ES2340902B1 (es) | 2011-05-03 |
Family
ID=41319881
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES200802002A Expired - Fee Related ES2340902B1 (es) | 2008-07-01 | 2008-07-01 | Composicion farmaceutica con glicosaminoglicanos y su uso en tratamiento de ulceras cronicas. |
| ES09772593.1T Active ES2476966T3 (es) | 2008-07-01 | 2009-06-30 | Composición farmacéutica con glicosaminoglicanos y su uso en tratamiento de úlceras crónicas |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES09772593.1T Active ES2476966T3 (es) | 2008-07-01 | 2009-06-30 | Composición farmacéutica con glicosaminoglicanos y su uso en tratamiento de úlceras crónicas |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20110201572A1 (enExample) |
| EP (1) | EP2308497B1 (enExample) |
| JP (1) | JP2011526608A (enExample) |
| CN (1) | CN102176915A (enExample) |
| AU (1) | AU2009265623B2 (enExample) |
| BR (1) | BRPI0913839A2 (enExample) |
| CA (1) | CA2766483C (enExample) |
| CY (1) | CY1115780T1 (enExample) |
| DK (1) | DK2308497T3 (enExample) |
| ES (2) | ES2340902B1 (enExample) |
| MX (1) | MX2010014552A (enExample) |
| PL (1) | PL2308497T3 (enExample) |
| PT (1) | PT2308497E (enExample) |
| RU (1) | RU2011103459A (enExample) |
| WO (3) | WO2010000905A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10705037B2 (en) | 2016-07-19 | 2020-07-07 | Laboratorios Farmaceuticos Rovi, S.A. | Method for the analysis of glycosaminoglycans, and their derivatives and salts by nuclear magnetic resonance |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2357601B1 (es) * | 2011-01-26 | 2012-03-21 | Laboratorios Farmacéuticos Rovi, S.A. | Procedimiento de preparación de derivados de glicosaminoglicanos donadores de óxido n�?trico y su uso en tratamiento de úlceras crónicas. |
| JP2012245943A (ja) * | 2011-05-31 | 2012-12-13 | Hitachi Automotive Systems Ltd | 制御装置 |
| JP5942133B2 (ja) * | 2012-09-11 | 2016-06-29 | 学校法人関西文理総合学園 | 蛍光プローブ及びこれを用いた酵素活性検出方法 |
| AU2016235662B2 (en) * | 2015-03-20 | 2020-07-30 | Aarhus Universitet | Inhibitors of PCSK9 for treatment of lipoprotein metabolism disorders |
| CN111194220B (zh) * | 2017-09-05 | 2024-06-18 | 黄玲惠 | 用于治疗缺血的肝素组合物 |
| CN114072430B (zh) * | 2020-04-27 | 2023-07-28 | 罗威制药股份有限公司 | 低分子量肝素获取程序以及由此获得的低分子量肝素 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES8206555A1 (es) * | 1980-05-14 | 1982-08-16 | Pharmindustrie | Procedimiento de preparacion de mezclas de polisacaridos sulfatados. |
| EP1033375A1 (en) * | 1997-11-20 | 2000-09-06 | Ikuo Yamashina | Low-molecular heparin modification and remedy for skin ulcer |
| EP1070503A1 (en) * | 1999-07-23 | 2001-01-24 | Laboratorios Farmaceuticos Rovi, S.A. | Compositions comprising very low molecular weight Heparin |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6004A (en) * | 1849-01-09 | chinnqck | ||
| CH636888A5 (fr) * | 1977-08-08 | 1983-06-30 | Choay Sa | Heparines purifiees et leur preparation. |
| CA1136620A (en) * | 1979-01-08 | 1982-11-30 | Ulf P.F. Lindahl | Heparin fragments having selective anticoagulation activity |
| IT1245907B (it) * | 1991-05-17 | 1994-10-25 | Alfa Wassermann Spa | Uso dei glicosaminoglicani nel trattamento della nefropatia diabetica e della neuropatia diabetica. |
| EP1357931A2 (en) | 2001-01-08 | 2003-11-05 | Human Genome Sciences, Inc. | Keratinocyte growth factor-2 |
| CU23043A1 (es) | 2001-12-20 | 2005-05-20 | Ct Ingenieria Genetica Biotech | Composicion farmaceutica que contiene factor de crecimiento epidrmico (egf) para la prevencion de la amputacion de pie diabetico. |
| BR0309707A (pt) | 2002-05-02 | 2005-02-09 | Pfizer Prod Inc | Tratamento de diabetes e complicações diabéticas com inibidores nhe-1 |
| US20060040896A1 (en) * | 2004-08-18 | 2006-02-23 | Paringenix, Inc. | Method and medicament for anticoagulation using a sulfated polysaccharide with enhanced anti-inflammatory activity |
| CU23388B6 (es) | 2006-01-31 | 2009-07-16 | Ct Ingenieria Genetica Biotech | Composición farmacéutica de microesferas para prevenir la amputación del pie diabético |
-
2008
- 2008-07-01 ES ES200802002A patent/ES2340902B1/es not_active Expired - Fee Related
-
2009
- 2009-06-30 WO PCT/ES2009/070265 patent/WO2010000905A1/es not_active Ceased
- 2009-06-30 EP EP09772593.1A patent/EP2308497B1/en active Active
- 2009-06-30 US US13/001,895 patent/US20110201572A1/en not_active Abandoned
- 2009-06-30 CN CN2009801338633A patent/CN102176915A/zh active Pending
- 2009-06-30 ES ES09772593.1T patent/ES2476966T3/es active Active
- 2009-06-30 BR BRPI0913839A patent/BRPI0913839A2/pt not_active Application Discontinuation
- 2009-06-30 DK DK09772593.1T patent/DK2308497T3/da active
- 2009-06-30 CA CA2766483A patent/CA2766483C/en not_active Expired - Fee Related
- 2009-06-30 PL PL09772593T patent/PL2308497T3/pl unknown
- 2009-06-30 PT PT97725931T patent/PT2308497E/pt unknown
- 2009-06-30 JP JP2011515493A patent/JP2011526608A/ja active Pending
- 2009-06-30 WO PCT/ES2009/070264 patent/WO2010000904A1/es not_active Ceased
- 2009-06-30 AU AU2009265623A patent/AU2009265623B2/en not_active Ceased
- 2009-06-30 RU RU2011103459/15A patent/RU2011103459A/ru unknown
- 2009-06-30 MX MX2010014552A patent/MX2010014552A/es active IP Right Grant
- 2009-06-30 WO PCT/ES2009/070266 patent/WO2010000906A1/es not_active Ceased
-
2013
- 2013-09-05 US US14/018,840 patent/US9211305B2/en not_active Expired - Fee Related
-
2014
- 2014-07-14 CY CY20141100529T patent/CY1115780T1/el unknown
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES8206555A1 (es) * | 1980-05-14 | 1982-08-16 | Pharmindustrie | Procedimiento de preparacion de mezclas de polisacaridos sulfatados. |
| EP1033375A1 (en) * | 1997-11-20 | 2000-09-06 | Ikuo Yamashina | Low-molecular heparin modification and remedy for skin ulcer |
| EP1070503A1 (en) * | 1999-07-23 | 2001-01-24 | Laboratorios Farmaceuticos Rovi, S.A. | Compositions comprising very low molecular weight Heparin |
Non-Patent Citations (5)
| Title |
|---|
| BRATT et al. Low molecular weight heparin (KABI 2165, Fragmin): 20, 21\\ pharmacokinetics after intravenous and subcutaneous administration in human volunteers. Thrombosis Research. Junio 1986. Vol 42(5), páginas 613-620, todo el documento. * |
| GUERRINI M. et al. Low molecular weight heparins: Structural 1-10, 12\\ differentiation by bidimensional nuclear magnetic resonance spectroscopy. Seminars in Thrombosis and Hemostatis. 2007. Vol 33(5), páginas 478-489. ISSN 0094-617. Especialmente, página 484- página 486, sección "{}monosaccharide composition of LMWHs"{} * |
| JORNESKOG G. et al. Low molecular weight heparin seems to 13-15, 21\\ improve local capillary circulation and healing of chronic foot ulcers in diabetic patients. Vasa. 1993. Vol 22(2), páginas 137- 142. ISSN 0301-1526. Especialmente, página 138 - página 139, secciones "{}study procedure"{} y "{}ulcer area and nutritional ski microcirculation"{}. * |
| KALANI M. et al. Effect of Dalteparin on healing of chronic 13-15, 21\\ foot ulcers in diabetic patients with pheripheral arterial occlusive disease. Diabetes care. Septiembre 2003. Vol 26(9), páginas 2575-2580. ISSN 0149-5992. Especialmente, página 2576- página 2578, secciones "{}randomization"{} y "{}ulcer outcome"{}. * |
| MUÑIZ GAVILAN A. Tinzaparina. Hoja de evaluación de Medicamentos 18, 19\\ de Castilla La Mancha. INSALUD. 2000. Vol 1(5), páginas 1-2. Especialmente, página 2, tabla 1. * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10705037B2 (en) | 2016-07-19 | 2020-07-07 | Laboratorios Farmaceuticos Rovi, S.A. | Method for the analysis of glycosaminoglycans, and their derivatives and salts by nuclear magnetic resonance |
| US10809212B2 (en) | 2016-07-19 | 2020-10-20 | Laboratorios Farmacéuticos Rovi, S.A. | Method for the analysis of glycosaminoglycans, and their derivatives and salts by nuclear magnetic resonance |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2010000906A1 (es) | 2010-01-07 |
| CA2766483C (en) | 2017-01-17 |
| DK2308497T3 (da) | 2014-07-14 |
| CN102176915A (zh) | 2011-09-07 |
| ES2476966T3 (es) | 2014-07-15 |
| CA2766483A1 (en) | 2010-01-07 |
| JP2011526608A (ja) | 2011-10-13 |
| RU2011103459A (ru) | 2012-08-10 |
| US9211305B2 (en) | 2015-12-15 |
| EP2308497A1 (en) | 2011-04-13 |
| WO2010000905A1 (es) | 2010-01-07 |
| AU2009265623B2 (en) | 2014-11-20 |
| EP2308497B1 (en) | 2014-04-16 |
| WO2010000904A1 (es) | 2010-01-07 |
| MX2010014552A (es) | 2011-04-26 |
| PL2308497T3 (pl) | 2014-10-31 |
| US20110201572A1 (en) | 2011-08-18 |
| ES2340902A1 (es) | 2010-06-10 |
| BRPI0913839A2 (pt) | 2015-10-20 |
| CY1115780T1 (el) | 2017-01-25 |
| AU2009265623A1 (en) | 2010-01-07 |
| US20140066402A1 (en) | 2014-03-06 |
| PT2308497E (pt) | 2014-07-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zhang et al. | The clinical use of Fondaparinux: A synthetic heparin pentasaccharide | |
| ES2340902B1 (es) | Composicion farmaceutica con glicosaminoglicanos y su uso en tratamiento de ulceras cronicas. | |
| US7902171B2 (en) | Composition for treating inflammatory diseases | |
| JP2003506310A (ja) | ヘパリン及びアデノシドａ２アゴニストの組合せで、又はアデノシンでの閉塞性末梢血管疾患及び冠状動脈疾患の治療 | |
| PT1385492E (pt) | Utilização de derivados de ácido hialurónico para a inibição de artrites inflamatórias | |
| JP2009535341A (ja) | 血液凝固を軽減するためのフコイダン | |
| CN104203256B (zh) | 用于引产的包含硫酸化的葡糖胺聚糖的联合治疗 | |
| EP0526578A1 (en) | Composition and method for topical treatment of damaged or diseased tissue | |
| Franzè et al. | Influence of chemical and structural features of low molecular weight heparins (LMWHs) on skin penetration | |
| EP0881904B1 (en) | Topical pharmaceutical composition containing heparin | |
| WO2011038047A1 (en) | Methods of treatment with a low molecular weight heparin composition | |
| Schmitz et al. | Oral heparin delivery: design and in vivo evaluation of a stomach-targeted mucoadhesive delivery system | |
| JP4051099B2 (ja) | 低分子化ヘパリン、その製造法及び医薬組成物 | |
| AU701014B2 (en) | Treatment of disease and conditions associated with macrophage infiltration in particular stroke and myocardial infarction | |
| EP1337261B1 (fr) | Medicament anti-inflammatoire a base de sulfate de laminarine | |
| EA032372B1 (ru) | Комбинация гликозаминогликанов и циклодекстринов | |
| CN1235597C (zh) | 用于创伤护理的药物组合物 | |
| RU2642612C2 (ru) | Комплексы на основе хондроитина для чрескожного всасывания | |
| JP2001187740A (ja) | 創傷治療剤 | |
| BRPI0801477A2 (pt) | galactana sulfatada com atividade antitrombótica, composição farmacêutica, seus usos e método para tratamento ou profilaxia de trombose arterial ou venosa | |
| ES2357601B1 (es) | Procedimiento de preparación de derivados de glicosaminoglicanos donadores de óxido n�?trico y su uso en tratamiento de úlceras crónicas. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EC2A | Search report published |
Date of ref document: 20100610 Kind code of ref document: A1 |
|
| FG2A | Definitive protection |
Ref document number: 2340902 Country of ref document: ES Kind code of ref document: B1 Effective date: 20110503 |
|
| FD2A | Announcement of lapse in spain |
Effective date: 20211202 |